Five-inch HORN removed from man's back was skin cancer
WARNING: GRAPHIC CONTENT: The horn was the result of a common cancer called a squamous cell carcinoma (SCC). Doctors in Chester removed it and covered the hole with a skin graft. (Source: the Mail online | Health)
Source: the Mail online | Health - December 30, 2019 Category: Consumer Health News Source Type: news
The man with a five-inch HORN sticking out of his back: Labourer's lump turned out to be skin cancer
WARNING: GRAPHIC CONTENT: The horn was the result of a common cancer called a squamous cell carcinoma (SCC). Doctors in Chester removed it and covered the hole with a skin graft. (Source: the Mail online | Health)
Source: the Mail online | Health - December 30, 2019 Category: Consumer Health News Source Type: news
ASTRO Issues Recs for Radiation Tx of Basal, Squamous Cell Carcinoma
RT recommended as primary treatment for BCC, cSCC patients who are not surgical candidates (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 24, 2019 Category: Cancer & Oncology Tags: Dermatology, Oncology, Radiology, Surgery, Journal, Source Type: news
ASTRO Issues Recs for Radiation Tx of Basal, Squamous Cell Carcinoma
TUESDAY, Dec. 24, 2019 -- In an executive summary of an American Society for Radiation Oncology clinical practice guideline, published online Dec. 9 in Practical Radiation Oncology, recommendations are presented for the use of radiation therapy (RT)... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 24, 2019 Category: Pharmaceuticals Source Type: news
Clinical Guideline Released for Radiation Therapy in Treating Patients with Skin Cancer
Recommendations defined when and how radiation therapy should be used to treat patients with basal cell carcinoma and cutaneous squamous cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - December 20, 2019 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
FDA Grants Fast Track Designation to Tipifarnib for the Treatment of Patients with HNSCC
The drug candidate tipifarnib (Zarnestra) is being clinically studied for the treatment of patients with HRAS-mutant head and neck squamous cell carcinoma after progression on platinum therapy. (Source: CancerNetwork)
Source: CancerNetwork - December 16, 2019 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
Squamous Cell Carcinoma Arising From an Epidermal Cyst Squamous Cell Carcinoma Arising From an Epidermal Cyst
In this report, a patient presented with a rare malignant transformation of an epidermal cyst. How was this case successfully treated, and what was the outcome?ePlasty, Open Access Journal of Plastic Surgery (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 10, 2019 Category: Consumer Health News Tags: Plastic Surgery & Aesthetic Medicine Journal Article Source Type: news
ASTRO issues new guideline on radiation therapy for basal, squamous cell skin cancers
(American Society for Radiation Oncology) A new clinical guideline from the American Society for Radiation Oncology (ASTRO) provides recommendations on the use of radiation therapy to treat patients diagnosed with the most common types of skin cancers. The guideline details when radiation treatments are appropriate as stand-alone therapy or following surgery for basal and cutaneous squamous cell carcinomas (BCC, cSCC), and it suggests dosing and fractionation for these treatments. ASTRO's first guideline for skin cancer published in Practical Radiation Oncology. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 10, 2019 Category: Cancer & Oncology Source Type: news
NOTCH1 signaling in oral squamous cell carcinoma via a TEL2/SERPINE1 axis
In this study, the research team investigated NOTCH1 mutations in keratinocyte lines derived from OSCC biopsies that had been subjected to whole exome sequencing. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 4, 2019 Category: Cancer & Oncology Source Type: news
Incidence of Squamous Cell Carcinoma of the Anus Increasing
Greater increase seen for distant - stage and regional - stage SCCA than for localized - stage SSCA (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - November 20, 2019 Category: Cancer & Oncology Tags: Family Medicine, Gastroenterology, Gynecology, Internal Medicine, Oncology, Journal, Source Type: news
Incidence of Squamous Cell Carcinoma of the Anus Increasing
WEDNESDAY, Nov. 20, 2019 -- There has been an increase in the incidence of squamous cell carcinoma of the anus (SCCA) in the United States, according to a study published online Nov. 19 in the Journal of the National Cancer Institute.
Ashish A.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 20, 2019 Category: Pharmaceuticals Source Type: news
New advances in the treatment of advanced lung cancer
The University of Barcelona (UB) and Hospital Clínic de Barcelona collaborate with Boehringer Ingelheim Inc. to improve the efficiency of nintedanib, an antiangiogenic and antifibrotic drug, for the treatment of lung cancer. This public-private collaboration enabled researchers identify molecular mechanisms underlying the lack of efficiency of this drug in squamous cell carcinoma, a sub-type of non-small cell lung cancer, and the important role of smoking in this lack of effectivity. (Source: World Pharma News)
Source: World Pharma News - November 19, 2019 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
New advances in the treatment of advanced lung cancer
(University of Barcelona) The University of Barcelona (UB) and Hospital Cl í nic de Barcelona collaborate with Boehringer Ingelheim Inc. to improve the efficiency of nintedanib, an antiangiogenic and antifibrotic drug, for the treatment of lung cancer. This public-private collaboration enabled researchers identify molecular mechanisms underlying the lack of efficiency of this drug in squamous cell carcinoma, a sub-type of non-small cell lung cancer, and the important role of smoking in this lack of effectivity. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 19, 2019 Category: Cancer & Oncology Source Type: news
Putting a Price on Life: Is the Answer Outside Pharma?
To cure the previously incurable we must take two giant steps: the first towards better understanding the science behind a cure, and the second towards ensuring accessibility for those people in need of the treatment. Although there is still much to discover, we got the science right some time ago. The first gene replacement therapy – Gendicine (Shenzhen SiBiono GeneTech) – was approved in China in 2003 and has been successfully administered to more than 30,000 patients with head and neck squamous cell carcinoma. A single dose of this medication costs $400. Another example of early innovation is Neovasculgen (...
Source: EyeForPharma - November 4, 2019 Category: Pharmaceuticals Authors: Nicola Davies Source Type: news
Tipifarnib Shows Responses in HRAS-Mutant Head and Neck Cancers
A new inhibitor may help patients with a certain subset of head and neck squamous cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - October 30, 2019 Category: Cancer & Oncology Authors: Seth Augenstein Source Type: news
